Stay updated on Pembrolizumab for Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab for Hepatocellular Carcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page’s footer revision/version number was updated from v3.5.2 to v3.5.3, reflecting a minor site release rather than a change to the trial details.SummaryDifference0.1%

- Check26 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check55 days agoChange DetectedThe page revision label was updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision tag on the site changed from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check69 days agoChange DetectedAdded the long-form study title for Pembrolizumab in HBV-related hepatocellular carcinoma and later removed an alternate title variant, with related regulatory notes.SummaryDifference0.6%

- Check91 days agoChange DetectedRevision: v3.4.2 is now active, replacing v3.4.1. This update does not appear to change the study details or other critical information.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Hepatocellular Carcinoma Clinical Trial page.